Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing
Investing.com - Goldman Sachs has reiterated its Neutral rating and $27.00 price target on Pfizer (NYSE:PFE) following the pharmaceutical giant’s announcement to acquire Metsera. According to InvestingPro data, Metsera maintains a GOOD Financial Health score, with analyst price targets ranging from $50 to $77.
Pfizer revealed Monday its plans to purchase development-stage obesity-focused biotech company Metsera (MTSR) for up to $7.3 billion. The deal structure includes a $4.9 billion upfront enterprise value transaction, representing $47.50 per share and approximately a 45% premium to Metsera’s last closing price. InvestingPro analysis shows Metsera holds more cash than debt and maintains a healthy current ratio of 5.26, indicating strong liquidity.
The acquisition also includes contingent value rights with potential additional payments of up to $22.50 per share. This transaction aligns with Pfizer’s previously stated strategic focus on expanding its presence in internal medicines and primary care, with particular emphasis on the cardiometabolic and obesity therapeutic areas.
Pfizer has maintained its commitment to the obesity space despite discontinuing its danuglipron program in April 2025. The company’s portfolio will now include Metsera’s injectable and oral peptide candidates targeting obesity.
The transaction is expected to close in the fourth quarter of 2025, with Pfizer planning to provide an updated financial outlook during its third-quarter 2025 earnings report.
In other recent news, Pfizer announced its proposed acquisition of Metsera for $4.9 billion, with the deal including an additional contingent value right that could increase the total transaction value to $7.3 billion. This acquisition is slated to close in the fourth quarter of 2025. Meanwhile, Wolfe Research has reiterated an Underperform rating on Pfizer, setting a price target of $25. The firm noted that Pfizer is expected to release topline data from VESPER-1 and interim data from VESPER-3 by the end of September 2025.
In related developments, Metsera has been in the spotlight with Cantor Fitzgerald maintaining an Overweight rating on its stock, highlighting the potential of its oral GLP-1 medications. Leerink Partners also initiated coverage on Metsera with an Outperform rating and a $77 price target, citing the company’s innovative obesity peptide-based therapeutics. Cantor Fitzgerald further emphasized that the upcoming months will be significant for Metsera, with several updates expected in its obesity treatment pipeline. These developments indicate a dynamic period ahead for both Pfizer and Metsera in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.